Last reviewed · How we verify

Fundació Sant Joan de Déu — Portfolio Competitive Intelligence Brief

Fundació Sant Joan de Déu pipeline: 3 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
citalopram (SSRI) citalopram (SSRI) marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Mental Health
NICE NICE marketed Other
Antidepressants Antidepressants marketed Neuroscience
Lactosa (placebo arm) Lactosa (placebo arm) phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 2 shared drug classes
  2. Merck Sharp & Dohme LLC · 2 shared drug classes
  3. Amgen · 1 shared drug class
  4. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
  7. Baxalta now part of Shire · 1 shared drug class
  8. Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundació Sant Joan de Déu:

Cite this brief

Drug Landscape (2026). Fundació Sant Joan de Déu — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-sant-joan-de-d-u. Accessed 2026-05-17.

Related